UK Markets closed

GlaxoSmithKline plc (GLAXF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
21.10+0.27 (+1.32%)
At close: 02:28PM EDT
Sign in to post a message.
  • R
    Russell
    This stock has held up well during this downturn. When the market turns this will soar.
  • T
    Tim
    NEver in a clinical trial has 100% cure happened to a stage 3 or more cancer with all participants. Imagine this fact working on a bigger clinical trial. I am excited and not cashing out of this investment until it adds a decimal place.
  • J
    Jess
    100% positive results for a possible cure to cancer and it's not even up a point. I'm about to lose my faith in the stock market.
  • I
    Iscee
    Dr. Luis A. Diaz Jr. of Memorial Sloan Kettering Cancer Center, an author of a paper published Sunday in the New England Journal of Medicine describing the results, which were sponsored by drug company GlaxoSmithKline, said he knew of no other study in which a treatment completely obliterated a cancer in every patient.
  • C
    Cal
    $GSK 🔥💉

    "In a small study of 14 rectal cancer patients, researchers at Memorial Sloan Kettering Cancer Center (MSKCC) published results where **100% of the 12 patients*** who completed treatment went into remission."

    Yes, it was a really small study...but the results were amazing.
  • G
    Gerald
    "Qualifying GSK shareholders will be entitled to receive one Haleon share for each GSK share held by them and will continue to own their GSK shares unless they sell or transfer them in the ordinary course."
  • A
    Andrew
    The new cancer drug could revolutionize cancer treatments and who knows, maybe a cure?
  • G
    Gerald
    For some time now, Yahoo has been showing a 2726.53p price as the top of the 52-week range. Can't be...
  • s
    scott
    @yahoo finance. you need to check the 52week high price. It’s WRONG. #NOT2726p
  • J
    Jeff
    GSK has a drug that cures cancer and the Shares price goes down! I understand it's a small trial, but are you kidding me , this could be life Changing/SAVING for millions of people!
  • A
    Anonymous
    Help, I am new to this stock. Thinking of buying at open on Monday Today NE Journal of Medicine report a small study of patients with rectal cancer ALL were 100% cured. Thoughts?? Why is this not a screaming BUY BUY BUY??
  • R
    Richard
    Is this new cancer drug, 'dostarlimab' a GSK drug? And what is the connection with the company, Tesaro? This should be a major news story?
  • A
    Anonymous
    Thanks again. I have purchased some stock today with a 5 year time line. Let’s see. I think this very small trial ( reported ) results allows the exploring scientists to find the “ key” to other cancers. So yes buying this stock ( as with all stocks) is a bet on the future. Good luck to everyone. Happy stock picking.
  • J
    Johan
    Last year GSK said: if everything plays out, Jemperli could eventually reach £1 billion to £2 billion in peak sales, GSK estimates.

    That's no match for Keytruda, which registered $4.2 billion sales in the second quarter alone after a 20% year-over-year growth at constant currencies.

    So Keytruda has $16 billion.

    If Jemperli becomes the better drug....then the sky is the limit.
  • S
    SOD
    I don’t think Sloan Kettering would let them go out on a limb like this. Sounds fantastic, not only as an investment but the major changes in hope for a cure
  • R
    Really
    Stock prices rise and fall for a multitude of reasons all the time, though few reasons get noticed or mentioned by the press.
    GSK has some great things going -- the reorganization and new drugs are good examples. The reorganization creates uncertainty which means people are unsure and nervous about what the two new companies will look like. When it happens, that fear goes away. So, if one has confidence in the arrangement, buying before it happens could be a bargain.
    The new drugs look good but with such a large company they represent a relatively smaller gain than they would for a small company with the same drug candidates.
    A big driver for price is interest rates. As interest rates rise, the market value of "dividend stocks" tends to drop because some investors sell to lock in higher rates elsewhere.
    The point is that no one thing generally is responsible for price movement except when there is panic or news that is overvalued one way or the other.
    In my view, GSK represent a buy today compared to alternatives.
    Good luck, longs.
  • I
    It’s go time 🚀 🐮
    Possible cure to cancer and it’s up 1.45% 🫤 👀
  • C
    Chari
    Its a dividend stock. And it has its place in your portfolio.
  • J
    Johan
    Dostarlimab, Jemperli is original an Anab drug.

    Anab would get 8% on all sales below 1 billion.

    Above 1 billion, Anab will get 12% to 25%

    Anab sold those 8% rights for $250 million

    Anab still has the 12% to 25% rights.

    Tesaro licensed the drug from Anab.

    If this trial has really cured 18 cancers....then I bet that GSK will buy Anab to avoid those payments.

    Because....it could be that within 5 to 7 years, Jemperli sales overtakes Keytruda sales ($10 billion/year)
    10 billion would mean that GSK must pay Anab $1.7 billion/year

    And today, nothing is sure, maybe Anab accept a buy out for $2 billion. ($65/share)
  • R
    Rich
    If Unilever and others were rejected pre split, makes sense they target the new company after the breakup. I'm sticking around to see what happens. MERK